Search

Author/Creator Stankevich, E

1. 1151PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study. (23rd October 2018)

Authors:
Pishvaian, M J; Weiss, G J; Falchook, G S; Yee, N; Gil-Martin, M; Shahda, S; Moreno, V; Brana, I; Crittenden, M; Formenti, S; Al-Rajabi, R; Papadopoulos, K P; Stankevich, E; Feng, M; Li, J; Mathias, M; Kroog, G; Lowy, I; Fury, M G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1162PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). (23rd October 2018)

Authors:
Moreno, V; Gil-Martin, M; Johnson, M; Aljumaily, R; Lopez Criado, P; Northfelt, D W; Crittenden, M; Jabbour, S; Rosen, L; Garrido Lopez, P; Hervás Morón, A; Rietschel, P; Mohan, K K; Li, J; Stankevich, E; Rowlands, T; Feng, M; Lowy, I; Fury, M G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1240TiPPhase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy. (23rd October 2018)

Authors:
Lewis, K D; Fury, M G; Stankevich, E; Mathias, M; Mohan, K K; Li, S; Nunnink, K; Perry, C; Narwal, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1292PPhase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. (23rd October 2018)

Authors:
Owonikoko, T K; Papadopoulos, K P; Gil-Martin, M; Moreno, V; Salama, A K; Calvo, E; Safran, H; González-Martín, A; Aljumaily, R; Mahadevan, D; Niu, J; Kal Mohan, K; Li, J; Stankevich, E; Mathias, M; Lowy, I; Fury, M G; Babiker, H M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 71PPhase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. (17th December 2018)

Authors:
Owonikoko, T K; Papadopoulos, K P; Johnson, M L; Gil Martín, M; Moreno, V; Salama, A K; Calvo, E; Yee, N S; Safran, H; Aljumaily, R; Mahadevan, D; Niu, J; Kal Mohan, K; Li, J; Stankevich, E; Mathias, M; Lowy, I; Fury, M G; Babiker, H M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 72PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). (17th December 2018)

Authors:
Moreno, V; Gil-Martin, M; Johnson, M L; Aljumaily, R; Lopez Criado, P; Northfelt, D W; Crittenden, M; Jabbour, S; Rosen, L; Garrido, P; Hervás Morón, A; Rietschel, P; Mohan, K K; Li, J; Stankevich, E; Feng, M; Lowy, I; Fury, M G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study. (17th December 2018)

Authors:
He, A R; Weiss, G J; Falchook, G; Yee, N S; Gil-Martin, M; Shahda, S; Moreno, V; Brana, I; Crittenden, M; Formenti, S; Al-Rajabi, R; Papadopoulos, K P; Pishvaian, M J; Stankevich, E; Feng, M; Li, J; Mathias, M; Kroog, G; Lowy, I; Fury, M G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 74PPhase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). (17th December 2018)

Authors:
Babiker, H M; Brana, I; Mahadevan, D; Owonikoko, T K; Calvo, E; Rischin, D; Moreno, V; Papadopoulos, K P; Crittenden, M; Formenti, S; Giralt, J; Garrido, P; Hervás Morón, A; Mohan, K K; Fury, M G; Lowy, I; Stankevich, E; Feng, M; Li, J; Mathias, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 97P Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti–PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC). (15th December 2019)

Authors:
Rischin, D; Khushalani, N I; Schmults, C D; Guminski, A; Chang, A L S; Lewis, K D; Lim, A M; Hernandez-Aya, L; Hughes, B G M; Schadendorf, D; Hauschild, A; Stankevich, E; Booth, J; Li, S; Chen, Z; Desai, J; Lowy, I; Fury, M G; Migden, M R
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search